Natural Alternatives International, Inc. Announces 2026 Q2 and YTD Results
February 13, 2026 16:30 ET | Source: Natural Alternatives International Inc CARLSBAD,…
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2026
US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million…
Ocean Tomo Releases 2025 Intangible Asset Market Value Study Results
50-year study of the US market and 20 years of foreign market…
Vistin Pharma ASA: Fourth quarter and preliminary 2025 financial results
Oslo, Norway, 12th of February 2026 Vistin Pharma ASA (VISTN) today announces…
Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026
Exceeding latest 2025 guidance following a strong performance from both commercial arms…
Cellebrite Announces Record Fourth-Quarter and Full-Year 2025 Results
Total ARR grew 21% to $480.8 million; Revenue grew 18% to $128.8 million…
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026 06:00 ET | Source: Upstream Bio – Verekitug provided…
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. (OTCQB: BIXT) today…
SEMI Reports 2025 Annual Worldwide Silicon Wafer Shipments and Revenue Results
Shipments Increase in 2025 Amid Strong AI-driven Demand, While Revenue SoftensMILPITAS, Calif.,…
MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease
TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology…
